PO-0985: Anti-GRP 78 antibodies bind specifically to cancers enhance efficacy of radiotherapy in cancer  by Dadey, D. et al.
S478                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
 
Material and Methods: Chemically synthesized, RGD-/PEG- 
functionalized gold nanoparticles (RGD:AuNP; ≈2 -3 nm) were 
characterized using STEM, TEM, and LIBS imaging. Following 
clonogenic assay, radiation damage was induced in Panc1 
xenografts with 10 Gy and 220 kVp (Xtrahl, Inc). γ-H2AX, 3D-
(confocal) vessel imaging and IHC were performed. 
 
Results: Tumor vessel-targeted gold nanoparticles were 
subjected to conformal image-guided irradiation in Panc-1 
tumor xenograft to induce tumor vascular disruption. By 
specifically targeting the early angiogenic tumor 
endothelium, RGD:AuNP circumvent the dense stromal 
diffusion pathways that often limits the penetration and 
permeation of anti-cancer drugs/ nanoparticles to the cancer 
cells - a limitation of current radiosensitization approaches. 
In vitro testing in HUVEC displayed ≥3 -fold difference 
(***P<0.0001) in radiation damage in the +RGD:AuNP/+IR 
compared to the controls. More to it, the sub-millimeter 
accuracy of image-guided radiation therapy facilitated 
improved therapeutic efficacy (95%-100% tumor dose 
distribution) and less off-target toxicities. Quantification of 
the DNA-strand breaks (by γH2AX) showed ≈3 -fold increase 
(P<0.001) in the radiation specific DNA damage in the 
'nanoparticle-radiation' cohort (+RGD:AuNP/+IR: 57%) 
compared to the 'radiation' group (−RGD:AuNP/+IR:19%) and 
almost ≈10 -fold difference (P<0.001) compared to 
(+RGD:AuNP/−IR: 6% and −RGD:AuNP/−IR: 6%). 
 
Conclusion: This dual-targeting strategy holds great 
translational potential in radiation oncology. The resulting 
vascular disruption substantially improved the therapeutic 
outcome and subsidized the radiation/ nanoparticle toxicity, 
extending its utility to intransigent/ non-resectable tumors 
that barely respond to standard therapies. This abstract 
presents the first in-depth experimental investigation of 
tumor vascular disruption with nanoparticles, a novel 
strategy in radiation therapy. 
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Purpose or Objective: Inhibition of checkpoint kinases Wee1 
or Chk1 causes G2-checkpoint abrogation and mitotic 
catastrophe, particularly in p53 defective tumors. Based on 
this, Wee1 and Chk1 inhibitors are currently in clinical trials, 
combined with radiation or chemo-therapy. However, our 
previous work has shown that inhibition of Wee1 or Chk1 also 
causes DNA breakage in S-phase, largely due to high Cyclin-
Dependent-Kinase (CDK)-activity followed by unscheduled 
replication initiation. Furthermore, recent work by others has 
shown synergistic anti-cancer effects after combined Wee1 
and Chk1 inhibition. The aim of this study was to investigate 
whether S-phase DNA damage may contribute to the 
synergistic effects after combined Chk1/Wee1 inhibition. 
 
Material and Methods: Osteosarcoma U2OS and lung cancer 
A549, H460 and H1975 cells were exposed to the Wee1 
inhibitor MK1775 and/or the Chk1 inhibitors AZD7762, 
LY2606368, MK8776 and UCN01. The DNA damage marker 
gH2AX was analyzed in S-phase cells by flow cytometry. DNA 
damage signaling and inhibitory phosphorylation of CDK1 and 
CDK2 were examined by immunoblotting, and cell survival by 
clonogenic survival assays. CDK activity was measured in S-
phase cells by a novel flow cytometry barcoding method. In 
this method, CDK-dependent phosphorylations (antibodies to 
phospho-BRCA2 S3291, phospho-bMyb T487 and phospho-
Mpm2) versus DNA content (Hoechst staining) were examined 
in individual cells. Barcoding with Pacific Blue was included 
to reduce sample-to-sample variations. Loading of the 
replication initiation factor CDC45 was measured by a similar 
flow cytometry method and by immunoblotting after removal 
of unbound proteins by extraction with salt and detergent. 
 
Results: We observed a strong synergy in induction of S-phase 
damage after combined Wee1 and Chk1 inhibition. Also, 
clonogenic survival was strongly decreased after the 
combined treatment. Surprisingly, this synergy could not be 
explained by increased CDK-activity, as S-phase CDK-activity 
did not correlate with induction of DNA damage after Wee1 
and Chk1 inhibition. Wee1 inhibition caused a bigger increase 
in CDK-activity than Chk1 inhibition. However, Chk1 
inhibition caused more S-phase damage and loading of the 
replication factor CDC45. The combination of Wee1 and Chk1 
inhibitors further increased the CDC45 loading, and the 
extent of CDC45 loading correlated with DNA damage 
induction. 
 
Conclusion: We have shown for the first time that combined 
Wee1 and Chk1 inhibition causes synergistic S-phase DNA 
damage, due to distinct effects of Wee1 and Chk1 kinases in 
regulation of CDK activity and CDC45 loading, respectively. 
This synergy can explain the synergistic anti-cancer effects 
obtained by simultaneous Chk1/Wee1 inhibition. We propose 
that combined Chk1/Wee1 inhibition may be useful together 
with radiation therapy to eliminate radioresistant S-phase 
cells. 
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Purpose or Objective: Purpose: Glioblastoma demonstrates 
progression of disease within the high dose region of 
radiotherapy, in nearly all cases. The physiologic response 
within glioblastoma to radiation is in part dependent upon a 
pro-survival signaling. GRP78 was first described to regulate 
cellular stresses, including hypoglycemia, hypoxia and the ER 
stress response. GRP78 is an important regulator of cell 
stress, and binds to several pro-survival proteins. Antagonists 
to GRP78 include Kringle-5 and PAR4 which induce apoptosis 
in tumor vasculature endothelium and cancer cells. The 
molecular events that result from the ER stress response can 
enhance cell viability. GRP78 is overexpressed in poor 
prognosis cancers and is a molecular therapeutic target in 
poorly differentiated cancers. 
 
Material and Methods: Methods: We studied radiation 
induction of GRP78 by western immunoblot and flow 
cytometry. We used siRNA to knock down GRP78 in human 
GBM and NSCLC cell lines. In order to study the potential 
relationship between radiation dose and induction of ATF6 
activity, we treated D54 cells with 3 Gy and 6 Gy and 
analyzed GRP78 protein expression 48h after irradiation. We 
utilized Anti-GRP78 antibodies administered IV to mouse 
models of human cancer xenografts. We measured tumor 
growth delay using subcutaneous implants of human cancer 
xenografts. 
 
Results: Results: We found that radiation induces the 
expression of GRP78 in glioblastoma. Antibodies to GRP78 
enhanced radiation-induced cytotoxicity in glioblastoma but 
not normal cells. We found that radiation induced GRP78 
expression is regulated through the ER stress response, and 
that ATF6 is responsible for the transcriptional induction of 
GRP78. Knockdown of ATF6 abrogates GRP78 induction and 
enhanced cytotoxicity from radiation. Moreover interruption 
of GRP78 signaling enhances therapeutic effects of radiation. 
GRP78 antibodies enhanced cytotoxicity from radiation in 
human glioblastoma and NSCLC cell lines. We found that the 
levels of GRP78 protein were elevated at the 48 and 72h time 
points. Knockdown of ATF6 was sufficient to abrogate GRP78 
induction. We observed dose dependent increases in GRP78 
levels, which were reproducible when the experiment was 
repeated with LN827 cells. Similar changes were observed in 
GRP78 mRNA levels 48h after IR, where a 75% and 100% 
increase was observed in D54. Anti-GRP-78 antibodies bind 
specifically to irradiated cancers enhanced the efficacy of 
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radiotherapy in human cancer models in vitro and in mouse 
xenografts.  
 
Conclusion: Conclusion: GRP78 is a molecular target for the 
development of novel radiation sensitizing agents. Anti-
GRP78 antibodies enhance the efficacy of radiotherapy when 
administered IV to mouse models of human cancer. 
 
 
Poster: Radiobiology track: Tumour biology and 
microenvironment  
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Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-143 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor tissue samples were 
obtained from 40 patients. MiR-143 and STAT3 protein 
expression levels in these clinical samples and three ESCC 
cell lines were determined by quantitative RT–PCR and 
western blot. The relationship between expression level of 
miR-143 and clinical parameters were explored by one-way 
ANOVA. The specific targeting site of miR-143 in the 3’-UTR 
of STAT3 was identified using dual-luciferase reporter assays. 
Then, the effects of ectopic miR-143 or STAT3 expression on 
proliferation, cell cycle distribution, migration and invasion 
were determined in colony-forming assay, flow cytometry 
and transwell assay. The effect of miR-432 on tumor 
progression in vivo was determineded by performing tumor 
formation assay in nude mice. The role miR-143 in regulating 
cell cycle signaling, epithelial-mesenchymal transition and 
MMP up-regulation through repressing STAT3 was explored by 
analyzing the expression level of the downstream proteins. 
 
Results: MiR-143 expression was downregulated in 90% of the 
ESCC clinical samples and its expression level was associated 
with the lymph node metastasis(LNM), invasion and TNM 
stage in ESCC patients. Functional experiments showed that 
ectopic expression of miR-143 could inhibit tumor cell 
proliferation, migration and invasion by supressing STAT3 in 
vitro. Animal experiments showed that the size of 
subcutaneous tumors derived from miR-143 overexpressing 
cells were significantly smaller than that of empty vector 
expressing cells. Further studies verified that miR-143 might 
regulate cell cycle, EMT and MMP up-regulation by targeting 
STAT3 and hence, lead to the suppresion of ESCC cell 
proliferation, migration and invasion. 
 
Conclusion: Our study showed that miR-143 could act as a 
tumor suppressor through the inhibition of proliferation, 
migration and invasion by directly targeting STAT3 and 
subsequently mediates the downstream proteins. Thus, miR-
143 has significant value in clinical and may serve as a 
prognostic marker and therapeutic target in the future. 
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Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-432 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor specimens and 
adjacent tissue samples were obtained from 40 patients. 
Pearson correlation coefficients and linear regression model 
were used to explore the bivariate correlations between miR-
432 and IGSF3 expression levels and one-way ANOVA were 
used to estimate the relationship between expression level of 
miR-432 and clinical parameters. Then the effects of ectopic 
miR-432 or IGSF3 expression on proliferation and apoptosis 
were determined using miR-432 over-expression or 
knockdown cells in colony-forming assay and flow cytometry, 
and the effects on cell migration and invasion were 
determined using a transwell assay. On the other hand, 
bioinformatic analysis were performed to assess the 
relationship between IGSF3 and miR-432, and this 
relationship was identified using a dual-luciferase reporter 
assay. Finally, the biological consequences of miR-432-
mediated suppression of IGSF3 expression in ESCC cell lines 
were also determined by performing colony-forming assay, 
flow cytometry and trasnswell assay. 
 
Results: MiR-432 expression was downregulated in 93% 
(37/40) of the ESCC clinical samples and its expression level 
was associated with LNM and TNM stage in ESCC patients. 
Functional experiments showed that over-expression of miR-
432 induced an inhibition of cell proliferation, promotion of 
apoptosis and suppression of cell migraion and invasion in 
vitro by targeting IGSF3. 
 
Conclusion: In conclusion, our results established a 
functional link between miR-432 and IGSF3 expression in 
esophageal cancer, demonstrating that IGSF3 was directly 
repressed by miR-432, which subsequently effects the tumor 
biological process. Collectively, this finding not only helped 
us understand the molecular mechanism of esophageal 
carcinogenesis, but also gave us a strong rationale to further 
investigate miR-432 as a potential biomarker and therapeutic 
target for esophageal cancer. 
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Purpose or Objective: Tumor cells are the major targets for 
classic anticancer treatment modalities. At the same time 
other cell types within the tumor microenvironment are also 
targeted and co-determine the treatment response. 
Resistances to specific treatment modalities are therefore 
not only linked to the mutated genetic background of the 
tumor cells but also to the interaction of tumor cells with the 
tumor microenvironment. Thus targeting of important 
elements of the microenvironment is a promising strategy to 
overcome treatment resistances in solid tumors. Here we 
mechanistically investigate in different clinically relevant 
microtubule-stabilizing agent (MSA)-refractory tumor models 
the potency of combined treatment modalities of MSAs, 
inhibitors of angiogenesis and ionizing radiation to overcome 
MSA-resistance. 
 
Material and Methods: Rationally designed single and 
combined treatment regimens of ionizing radiation, 
microtubule stabilizing (taxane, epothilone) and de-
stabilizing agents and anti-angiogenics compounds were 
investigated in genetically defined MSA-sensitive and MSA-
resistant lung and colon adenocarcinoma cell lines in vitro 
and in the corresponding tumor xenografts in vivo. 
 
Results: While MSAs potently inhibited A549wt and 
endothelial cell proliferation, no anti-proliferative effect was 
observed in the corresponding mutated MSA-resistant tumor 
cells. Importantly, MSAs did not block anymore pro-survival 
auto- and paracrine signaling from resistant tumor cells by 
downregulation of HIF1-alpha transcriptional activity and 
subsequent secretions of HIF-1alpha-mediated growth factors 
and cytokines like VEGF. Thereby continuous pro-survival 
